Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
RESEARCH TOOLSreports
ACAD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.15 - $24.27
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.71M
Market Cap
$3.05B
Enterprise Value$2.04B
Total Cash (Recent Filing)$319.59M
Total Debt (Recent Filing)$51.99M
Price to Earnings (P/E)13.3
Beta1.24
Next Earnings
May 13, 2025EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.36
Shares Outstanding166,788,510
10 Day Avg. Volume1,897,283
30 Day Avg. Volume1,712,175
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.18
Price to Cash Flow (P/CF)18.90
P/FCF Ratio18.90
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda20.90
Forecast
1Y Price Target
$26.14Price Target Upside44.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
ACADIA Pharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Earnings4Q24 results were better than expected, with Nuplazid and Daybue sales beating expectations.
Sales PerformanceNuplazid's 2025 net sales guidance is well above company and market expectations, suggesting strong performance for the brand.
Bears Say
Sales GuidanceDaybue's net sales guidance for 2025 falls short of market expectations, which could indicate potential challenges for the brand.
---
Ownership Overview
24.05% Insiders
15.15% Mutual Funds
0.31% Other Institutional Investors
37.31% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.15 and its highest was $24.27 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $3.05B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 67 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 26, 2025. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.216 by $0.644.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is <0.01.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 166,788,510 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.86 in its last earnings report, beating expectations of $0.216. Following the earnings report the stock price went up 1.789%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
---
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.14 (44.58% Upside)
$26.14 (44.58% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 514.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.06%
12-Months-Change
Fundamentals
Return on Equity
38.89%
Trailing 12-Months
Asset Growth
58.59%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
ACAD Company Deck
---
ACAD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial results, pipeline expansion, and global growth plans, but also acknowledged challenges in revenue guidance due to pricing and regulatory uncertainties. Despite these hurdles, the company remains optimistic about its future growth and strategic initiatives.Read More>---
ACAD Stock 12 Month Forecast
Average Price Target
$26.14
▲(44.58% Upside)
Technical Analysis
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+7.73%
reiterated a buy rating 9 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +7.73% per trade.
---